ERBB2 and breast cancer: Three serum proteins that have been approved by the FDA as biomarkers to monitor chemotherapy in patients with advanced breast cancer were included: cancer antigen 15-3 (CA15-3), carcinoembryonic antigen (CEA) and HER2/neu [2,12].